Chimerix, Inc. (NASDAQ:CMRX) Short Interest Down 6.7% in September

Chimerix, Inc. (NASDAQ:CMRX) saw a large decrease in short interest in September. As of September 30th, there was short interest totalling 1,800,000 shares, a decrease of 6.7% from the September 15th total of 1,930,000 shares. Currently, 2.3% of the company’s stock are sold short. Based on an average daily trading volume, of 456,700 shares, the short-interest ratio is presently 3.9 days.

Hedge Funds Weigh In On Chimerix

Institutional investors and hedge funds have recently modified their holdings of the stock. Koshinski Asset Management Inc. acquired a new stake in Chimerix during the first quarter worth about $42,000. Valeo Financial Advisors LLC boosted its position in Chimerix by 566.9% in the 3rd quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company’s stock worth $76,000 after purchasing an additional 69,505 shares in the last quarter. Marquette Asset Management LLC grew its stake in shares of Chimerix by 24.3% during the 1st quarter. Marquette Asset Management LLC now owns 116,009 shares of the biopharmaceutical company’s stock worth $123,000 after purchasing an additional 22,709 shares during the period. Marshall Wace LLP acquired a new position in shares of Chimerix in the 2nd quarter valued at $137,000. Finally, Acadian Asset Management LLC boosted its holdings in Chimerix by 15.5% during the first quarter. Acadian Asset Management LLC now owns 2,174,813 shares of the biopharmaceutical company’s stock worth $2,304,000 after buying an additional 291,981 shares in the last quarter. Institutional investors and hedge funds own 45.42% of the company’s stock.

Chimerix Price Performance

NASDAQ:CMRX traded up $0.01 during midday trading on Thursday, hitting $0.88. The company’s stock had a trading volume of 77,776 shares, compared to its average volume of 363,825. Chimerix has a fifty-two week low of $0.75 and a fifty-two week high of $1.30. The firm has a market cap of $78.87 million, a P/E ratio of -0.93 and a beta of 1.12. The firm’s 50 day moving average is $0.90 and its 200-day moving average is $0.92.

Chimerix (NASDAQ:CMRX) last released its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.23). The business had revenue of $0.13 million during the quarter, compared to analyst estimates of $1.26 million. During the same quarter in the previous year, the company earned ($0.21) EPS. As a group, analysts forecast that Chimerix will post -0.86 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on CMRX. Wedbush reissued an “outperform” rating and issued a $6.00 price target on shares of Chimerix in a report on Tuesday, August 13th. StockNews.com upgraded shares of Chimerix from a “sell” rating to a “hold” rating in a research note on Wednesday, August 21st. Finally, HC Wainwright restated a “buy” rating and set a $11.00 price target on shares of Chimerix in a research note on Wednesday, August 14th.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.